ReviewFrontiers in endocrinology2026
Nanogenomic synergy in Diabetes care: precision therapeutics for patients with multiple long-term conditions.
Review in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetes mellitus presents complex constellation of multiple long-term conditions (MLTCs) including cardiovascular, renal, metabolic, and neuroinflammatory disorders. This leads to clinical heterogeneity, polypharmacy, therapeutic disinterest, adverse outcomes, societal challenges, and glycaemic control management strategies. Precision medicine-based approach address this intricacy through alignment of therapeutic interventions with consideration of biological profiles. In this, nanogenomic synergy is a breakthrough, that gives detailed insight of genomic and epigenomics in context to advanced nanotechnology-based drug delivery system for personalized diabetes care. Genomics and transcriptomic profiling approach stratified the patients based on molecular drivers of diabetes and treatment responses, whilst nanotechnology facilitated the targeted, controlled and tissue specific systemic effect with minimal toxicity and off-target effects. This mini review will present the current evidence and understanding of clinical and biological obstacles in management of MLTC associated with diabetes mellitus and investigate the role of nano genomics through shard pathogenic pathways across comorbid conditions. Many key evidence nanotechnology platforms for genomic guidance in therapeutics were also covered. A nanogenomic synergy is a very innovative concept that could potentially break through one-size-fits-all approaches by allowing the redefinition of diabetic care for people living with multiple long-term diseases. This is achieved through precision, innovation, and a more encompassing approach to care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.